American Biotech Labs New Wound Care Products Receive Indian Government Approval for Sale

    India's Central Drugs Standard Control Organization (CDSCO - equivalent
    to FDA in the U.S.) grants approval for the sale of four new
    antimicrobial wound care products based on ABL's patented technology;
    study results show effectiveness against broad variety of pathogens,
    accelerated heal times

    ALPINE, UT, Sept. 17 /CNW/ - American Biotech Labs (ABL), creator of a
new class of products based on the company's patented nano-catalytic SilverSol
Technology(TM), today announced that the agency responsible for drug and
medical device oversight in India - Central Drugs Standard Control
Organization ("CDSCO") has approved four new ABL antimicrobial wound care
products for sale in India. CDSCO is the Indian counterpart to the U.S. FDA.
    The four new antimicrobial wound care products are based on ABL's
patented SilverSol Technology and include: a wound wash; a wound disinfectant;
an antimicrobial gel; and a patented antimicrobial wound care patch.
    "This approval by India's primary drug and medical device oversight
organization is a significant milestone for these products and for ABL," said
William D. Moeller PhD, Chairman of Clifton Mining Company (OTC: CFTN,
21-percent owner of ABL). "The approval validates the power and efficacy of
our technology for wound care. We believe India will be a large market for
these products."
    "The Indian government has recognized the tremendous potential benefits
these products can offer in accelerating heal time and reducing cost and
complications of infection - particularly in health care facilities," said
Keith Moeller, a Managing Director over sales and marketing for ABL. "We are
honored to be on the forefront of technology that can provide improved
healthcare outcomes to people around the globe."
    ABL will market and sell its new product line in India, consistently
identified as one of the world's largest and most dynamic markets, through its
partner Viridis Biopharma, headquartered in Mumbai, India. Viridis is a
supplier of bio-pharma products and medical devices throughout the Indian
    ABL is also currently awaiting 510K regulatory approvals for wound care
products in the United States and Singapore.
    Separately, recently-completed rigorous efficacy testing of these
products has shown strong results against a broad variety of resistant
microbes, including the multi-drug-resistant staph infection MRSA
(methycillin-resistant staph aureus), VRE (vancomycin-resistant enterococci)
and numerous other pathogens.

    About American Biotech Labs

    American Biotech Labs (ABL;, founded in
1998, utilizes patented processes and SilverSol Technology(TM) to create
singularly powerful and effective nano-catalytic silver products. In extensive
testing performed by a variety of respected laboratories and researchers,
ABL's silver hydrosol has consistently demonstrated the ability, without any
known toxic side effects, to destroy a wide range of bacteria, viruses, yeast,
and molds. ABL products have been approved by the U.S. EPA as a disinfectant
for dental water lines, and as a surface disinfectant for bacteria, yeast and
mold in hospital, residential, commercial and industrial settings. The
company's products have been the subject of a number of peer-reviewed articles
in professional journals and are sold worldwide at health food stores and by
medical professionals under the Silver Biotics(R) and ASAP Solution(R) brands,
and through a variety of private labels.

For further information:

For further information: Dr. Ken Friedman, President at (303) 642-0659;
Keith Moeller, Vice President at (801) 756-1414 or see the websites at and

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890